The landscape of type 2 diabetes management and cardiovascular risk reduction in the United States has been significantly reshaped with…
Read More
Novo Nordisk’s triple agonist UBT251 delivered up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, has announced promising results from a Phase 2 trial of…
Read More
Novo Nordisk Forges Landmark AI Partnership with OpenAI to Revolutionize Drug Development Amidst Intensifying Competition
The pharmaceutical industry is witnessing an unprecedented surge in artificial intelligence (AI) adoption, with Novo Nordisk, a global leader in…
Read More
Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide
A Deep Dive into the Trial Results CagriSema, a novel combination therapy comprising cagrilintide and semaglutide, delivered an average weight…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk has announced significant positive results from a Phase 2 trial of its experimental triple agonist, UBT251, reporting a…
Read More
Novo Nordisk sues Hims for GLP-1 patent infringement
The pharmaceutical giant Novo Nordisk has initiated legal proceedings against Hims & Hers Health, Inc., alleging patent infringement related to…
Read More
Novo Nordisk’s New Weight Loss Treatment CagriSema Shows Inferiority to Lilly’s Tirzepatide in Head-to-Head Trial
Novo Nordisk, a global leader in diabetes and obesity care, announced on Monday that its eagerly anticipated weight loss treatment,…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, recently announced compelling Phase 2 trial results for its investigational…
Read More
Eli Lilly’s Foundayo Secures FDA Approval, Challenging Novo Nordisk’s Oral Obesity Drug Dominance
The United States Food and Drug Administration (FDA) has granted approval to Eli Lilly and Company’s novel oral glucagon-like peptide-1…
Read More
Novo Nordisk Secures FDA Approval for Awiqli, a Once-Weekly Basal Insulin for Adults with Type 2 Diabetes
The United States Food and Drug Administration (FDA) has granted approval to Novo Nordisk for Awiqli (insulin icodec-abae) injection 700…
Read More
